Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

PBS broadens access to COPD triple therapy and lung cancer immunotherapy

FOT better than spirometry for identifying poor asthma control

Novel therapy success for ‘untreatable’ P. aeruginosa in CF lung transplant patient

RACP training program gets 79% approval rating from participants

Today’s disease names are less catchy, but also less likely to cause stigma

Pulmonary fibrosis

Idiopathic pulmonary fibrosis therapeutics coming of age: ATS 2016

By Marilyn Glassberg

20 Jun 2016

Dr Marilyn Glassberg recently attended the American Thoracic Society’s 2016 International Conference alongside 15,000 other pulmonary, critical care, and sleep researchers. She talks more about the conference in this blog, focusing particularly on idiopathic pulmonary fibrosis. My specific area of interest is idiopathic pulmonary fibrosis (IPF), an incurable and fatal disease characterized by a progressive ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories